Provid Pharmaceuticals (United States)
- Research works
- 29 ▼ 41% vs 2013–17
- Citations
- 512 17.6 per fractional work
- Top-10% rate
- 9.5% record average 16.5%
- Open access
- 19% world 28%
Not ranked overall: Provid Pharmaceuticals (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Chemistry, 10.1×. Every wedge is a field page.
Which keywords describe research at Provid Pharmaceuticals (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Reactive Oxygen Species, Complications, Photodynamic Therapy, Nanoparticles, Chemotherapy, Chronic Pain, Oxidative Stress and TGF-ß.
- Biosensors
- Immunotherapy
- Apoptosis
- Chronic Kidney Disease
- Hernia Repair
- Antibiotic Resistance
- Chronic Pain
- Photodynamic Therapy
- Reactive Oxygen Species
- Nanoparticles
- Epidemiology
- Oxidative Stress
- Complications
- Chemotherapy
- TGF-ß
- Cancer Therapy
- Mesh Techniques
- Graft Survival
- Gene Therapy
- Tumor Targeting
- Gene Expression
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 21 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 21 words, with their numbers
- Epidemiology2▲ 1.68×8 topics
- Nanoparticles2▲ 5.2×6 topics
- Oxidative Stress2▲ 3.8×12 topics
- Reactive Oxygen Species2▲ 13×4 topics
- Complications2▲ 12×3 topics
- Photodynamic Therapy2▲ 40×3 topics
- Chemotherapy2▲ 7.7×5 topics
- Chronic Pain2▲ 23×3 topics
- TGF-ß1▲ 28×3 topics
- Antibiotic Resistance1▲ 11×5 topics
- Cancer Therapy1▲ 7.0×5 topics
- Hernia Repair1▲ 167×1 topic
- Mesh Techniques1▲ 167×1 topic
- Chronic Kidney Disease1▲ 16×2 topics
- Graft Survival1▲ 41×2 topics
- Apoptosis1▲ 10.0×5 topics
- Gene Therapy1▲ 14×3 topics
- Immunotherapy1▲ 5.9×2 topics
- Tumor Targeting1▲ 29×2 topics
- Biosensors1▲ 6.0×2 topics
- Gene Expression1▲ 5.6×2 topics
Which research topics does Provid Pharmaceuticals (United States) publish most on?
By volume in 2022–2025: Antibiotic Resistance in Bacteria, Synthesis and Biological Evaluation, Antimicrobial Resistance in Staphylococcus and Cancer-related Molecular Pathways.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Antibiotic Resistance in Bacteria Molecular Medicine 0 works
- 2 Synthesis and Biological Evaluation Organic Chemistry 0 works
- 3 Antimicrobial Resistance in Staphylococcus Infectious Diseases 0 works
- 4 Cancer-related Molecular Pathways Oncology 0 works
- 5 Advanced Neural Network Applications Computer Vision and Pattern Recognition 0 works
- 6 Medical Image Segmentation Techniques Computer Vision and Pattern Recognition 0 works
- 7 Inhalation and Respiratory Drug Delivery Pulmonary and Respiratory Medicine 0 works
- 8 Brain Tumor Detection and Classification Neurology 0 works
- 9 Bacterial biofilms and quorum sensing Molecular Biology 0 works
- 10 Bacterial Genetics and Biotechnology Genetics 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Provid Pharmaceuticals (United States)'s research output changed?
Output in 2018–2022 was 41% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Monmouth Junction
- Tris Pharma (United States)
- United Silicon Carbide (United States)
- Knite (United States)
- PharmaSeq (United States)
- CytoSorbents (United States)
- Nanonex (United States)
- Diamir (United States)
- Xeme Biopharma (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.